Literature DB >> 19445735

Opioids in people with cancer-related pain.

Columba Quigley1.   

Abstract

INTRODUCTION: Up to 80% of people with cancer experience pain at some time during their illness, and most will need opioid analgesics. This review assesses how different opioid analgesics compare, in terms of both pain control and adverse effects, in people with cancer. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: what are the effects of opioids in treating cancer-related pain? We searched: Medline, Embase, The Cochrane Library, and other important databases up to July 2007 (BMJ Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 22 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: codeine, dihydrocodeine, transdermal fentanyl, hydromorphone, methadone, morphine, oxycodone, and tramadol.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19445735      PMCID: PMC2907984     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  19 in total

1.  Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study.

Authors:  Daniel Arbaiza; Oscar Vidal
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

2.  Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.

Authors:  S Ahmedzai; D Brooks
Journal:  J Pain Symptom Manage       Date:  1997-05       Impact factor: 3.612

3.  Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network.

Authors:  Pål Klepstad; Stein Kaasa; Nathan Cherny; Geoffrey Hanks; Franco de Conno
Journal:  Palliat Med       Date:  2005-09       Impact factor: 4.762

4.  Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain.

Authors:  J O Wong; G L Chiu; C J Tsao; C L Chang
Journal:  Acta Anaesthesiol Sin       Date:  1997-03

5.  Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.

Authors:  N A Hagen; N Babul
Journal:  Cancer       Date:  1997-04-01       Impact factor: 6.860

6.  Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.

Authors:  R van Seventer; J M Smit; R M Schipper; M A Wicks; W W A Zuurmond
Journal:  Curr Med Res Opin       Date:  2003       Impact factor: 2.580

7.  Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain.

Authors:  C H Wilder-Smith; J Schimke; B Osterwalder; H J Senn
Journal:  Ann Oncol       Date:  1994-02       Impact factor: 32.976

8.  Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.

Authors:  A J Clark; S H Ahmedzai; L G Allan; F Camacho; G L A Horbay; U Richarz; K Simpson
Journal:  Curr Med Res Opin       Date:  2004-09       Impact factor: 2.580

9.  Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home.

Authors:  S Mercadante; A Casuccio; A Agnello; R Serretta; L Calderone; L Barresi
Journal:  J Clin Oncol       Date:  1998-11       Impact factor: 44.544

10.  Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized, double-blind study.

Authors:  L Grochow; V Sheidler; S Grossman; L Green; J Enterline
Journal:  Pain       Date:  1989-08       Impact factor: 6.961

View more
  4 in total

1.  Bisphosphonate treatment may reduce osteoporosis risk in female cancer patients with morphine use: a population-based nested case-control study.

Authors:  C W-S Lee; C-H Muo; J-A Liang; S-N Chang; Y-J Chang; C-H Kao
Journal:  Osteoporos Int       Date:  2013-03-08       Impact factor: 4.507

Review 2.  Codeine, alone and with paracetamol (acetaminophen), for cancer pain.

Authors:  Carmen Straube; Sheena Derry; Kenneth C Jackson; Philip J Wiffen; Rae F Bell; Scott Strassels; Sebastian Straube
Journal:  Cochrane Database Syst Rev       Date:  2014-09-19

Review 3.  The Potential of Psychedelics for End of Life and Palliative Care.

Authors:  David B Yaden; Sandeep M Nayak; Natalie Gukasyan; Brian T Anderson; Roland R Griffiths
Journal:  Curr Top Behav Neurosci       Date:  2022

4.  Consumption trends and prescription patterns of opioids from 2011 to 2016: a survey in a Chinese city.

Authors:  Xiao Liu; Can Luo; Huizhen Dai; Wentong Fang
Journal:  BMJ Open       Date:  2019-03-01       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.